haematology

News in brief: 4 lessons from real world use of CAR-T cell therapy; COVID-19 problematic in post-ASCT patient; Top 10 Choosing Wisely recs for COVID-19

4 lessons from real world use of CAR-T cell therapy A review of CAR-T cell therapies in relapsed/refractory aggressive B-cell lymphoma has concluded that efficacy and safety in real-world experience supports the findings of pivotal trials. Axicabtagene ciloleucel (axi-cel) has a higher degree of toxicity and requires inpatient administration, but also appears to have the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic